The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
26-Mar-07
$1.0 billion
Target:
Wolters Kluwer Education
Acquiror:
Bridgepoint Capital Limited
Advised Bridgepoint Capital Limited on its acquisition of Wolters Kluwer Education, the pan-European educational publishing division of quoted Dutch-based information services and publishing company Wolters Kluwer NV
02-Jan-08
$NA
Target:
E. Brost & J. Funke GmbH & Co. KG (BFK KG) and its 25% stake in Otto Group
Acquiror:
Otto AG für Beteiligungen (investment vehicle of Otto family)
Advised the shareholders of BFK KG, comprising the families who also own German publisher WAZ Media Group, on the sale of their 25% holding in German retailing and services group Otto to the Otto family, which thereby regained full ownership of the business
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
27-Jul-11
$850 million
Target:
The Synovate Group
Acquiror:
Ipsos S.A.
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
12-Jul-12
$5.0 billion
Target:
Aegis Group plc
Acquiror:
Dentsu Inc.
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
03-Mar-14
$3.6 billion
Target:
hibu plc (formerly Yell Group plc)
Advised hibu, a full service provider of digital and print marketing services for SMEs and owner of print directory brands Yellow Pages (UK), Yellowbook (US) and Paginas Amarillas (Spain), on the comprehensive restructuring of its £2.2 billion balance sheet debt
08-Apr-14
$NA
Target:
ARTnews
Acquiror:
Skate Capital Corp.
Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
11-Aug-14
$NA
Target:
MannKind Corporation
Acquiror:
Sanofi
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
29-May-15
$4.1 billion
Target:
Telecity Group plc
Acquiror:
Equinix, Inc.
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
01-Dec-15
$NA
Target:
Allied Healthcare
Acquiror:
AURELIUS Investments
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
14-Dec-15
$NA
Target:
Specialized Anodized Extrusion Holding Switzerland AG (Spandex)
Acquiror:
Chequers Capital
Advised Gilde Buy Out Partners on the sale of Spandex, a specialized B2B distributor of graphic media and equipment to the signage and visual communications industry, to Chequers Capital
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
16-May-16
$874 million
Target:
Equinix Data Center Assets
Acquiror:
Digital Realty Trust
Advised Digital Realty Trust, the world's largest wholesale colocation services and data center solutions provider, on its acquisition of a portfolio of eight carrier-neutral European data centers from Equinix
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab